RxDoctor Payments Data

Judson Jones, NP

Nurse Practitioner · Baton Rouge, LANPI 1720492200

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,759in general payments, 2019–2025

Across 399 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$849
  • Novartis$777
  • Daiichi Sankyo Inc.$493
  • Johnson & Johnson$391
  • Incyte Corporation$336
  • Merck$335
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$1251%
  • Food & beverage$8,34195%
  • Education$2933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)37$849
Novartis46$777
Daiichi Sankyo Inc.20$493
Johnson & Johnson15$391
Incyte Corporation11$336
Merck15$335
Myriad Genetic Laboratories, Inc.4$317
Sanofi15$286
AbbVie9$271
Ipsen Biopharmaceuticals, Inc9$242
Lilly USA, LLC12$233
Pfizer12$226
Acrotech Biopharma Inc.4$211
AVEO Pharmaceuticals, Inc.10$204
Bayer10$204
E.r. Squibb & Sons, L.L.C.9$189
Amgen9$174
Exelixis Inc.8$152
Beigene USA, Inc.7$135
Pharmacyclics LLC, An Abbvie Company7$123
GSK6$120
Otsuka America Pharmaceutical, Inc.7$117
Pharmacosmos Therapeutics Inc.6$112
Akebia Therapeutics Inc6$111
Regeneron Healthcare Solutions, Inc.5$111
Bristol Myers Squibb6$108
Morphosys, US Inc.6$106
Genentech USA, Inc.5$105
Medtronic2$90
ADC Therapeutics America, Inc.4$87
Puma Biotechnology, Inc.5$86
Takeda Pharmaceuticals U.S.A., Inc.3$83
Adaptive Biotechnologies Corporation4$82
Gilead(2 entities)4$80
G1 Therapeutics, Inc.5$78
Servier Pharmaceuticals LLC4$78
Seagen Inc.4$78
Sanofi-aventis U.S. LLC1$75
EMD Serono, Inc.4$70
Blueprint Medicines Corporation3$69
Mallinckrodt Hospital Products Inc.3$61
Sobi, Inc2$56
Beone Medicines USA, Inc.3$55
Karyopharm Therapeutics Inc.3$53
Vifor Pharma, Inc.3$50
Fresenius USA Marketing, Inc.3$48
Jazz Pharmaceuticals Inc.2$43
Recordati_rare_diseases_inc.2$43
Eisai Inc.2$39
Astellas Pharma US Inc2$35
Ultragenyx Pharmaceutical Inc.2$32
Genmab U.S., Inc.1$30
OPKO Pharmaceuticals, LLC2$28
Sandoz1$26
Pharmaessentia USA Corporation1$25
Azurity Pharmaceuticals, Inc.1$21
Immunocore Limited1$21
Syndax Pharmaceuticals, Inc.1$20
Dendreon Pharmaceuticals LLC1$19
Stemline Therapeutics Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,759 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,600
Medicare patients
108
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$181,260
Lenalidomide11$136,030
EliquisApixaban15$9,609
Fentanyl28$4,297
Megestrol Acetate28$1,971
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen107$1,739
Letrozole66$1,544
Anastrozole33$1,080
Tamoxifen Citrate24$984
Prochlorperazine Maleate43$924
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$914
Gabapentin48$583
Oxycodone Hcl25$538
Tramadol Hcl30$531
Prednisone55$514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$35$181,26013 claims
PfizerEliquis$226$9,60915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →